Danaher Corporation (DHR) Stock: Price, Forecast & Analyst Target
Danaher Corporation (DHR) — MoonshotScore 68/100 (Strong band), calculated Oct 4, 2026. Price $214.06 (+1.09%), as of the Oct 2, 2026 trading session; market cap $150B. Expected results Oct 20, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 34.50× (market value Oct 2, 2026; cash Jun 26, 2026) · expected results Oct 20, 2026
Danaher Corporation · DHR · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Danaher sells laboratory, bioprocessing, diagnostic and applied-analysis systems, then supplies many of the reagents, consumables and services those workflows continue to require. Revenue has resumed growth, but the case now depends on whether that recovery can produce durable operating leverage while substantial debt remains ahead of liquid resources.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Danaher (DHR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but weak growth; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $6.26B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of 8
- expected results Oct 20, 2026
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 74 | Strong | |
| 68 | Strong | |
| 69 | Strong | |
| 69 | Strong | |
| 68 | Strong | |
| 68 | Strong |
The score was 68 in the stored Oct 3, 2026 snapshot and remains 68 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Business Quality -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $214.06 | |
| Change on the day | +1.09% | |
| 52-week range | $160.93–$242.80 | |
| Market capitalisation | $150B | |
| Price / earnings (trailing) | 37.89 | |
| Shares traded on the day | 3.89M | |
| Beta (volatility vs the S&P 500) | 0.81 | |
| Dividends per share (last 12 months) | $1.52 | |
| Dividend yield (last 12 months) | 0.71% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Danaher (DHR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 29, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the DHR film — every key number, told as a short cinematic story
~2 min · open the film
What is Danaher (DHR), and what does it report?
Short answer · as of
Danaher is not simply a medical-device manufacturer: its portfolio spans research instruments, bioprocess technologies, clinical diagnostics, water analysis and packaging-quality tools. Customers range from drug developers and research institutions to hospitals, laboratories and industrial operators, so reported revenue combines capital equipment with recurring reagents, consumables, software and service demand.
Research dated 2026-09-12.
Danaher is not simply a medical-device manufacturer: its portfolio spans research instruments, bioprocess technologies, clinical diagnostics, water analysis and packaging-quality tools. Customers range from drug developers and research institutions to hospitals, laboratories and industrial operators, so reported revenue combines capital equipment with recurring reagents, consumables, software and service demand. The recurring category supplies most revenue, making utilization of Danaher-supported workflows as important as new instrument purchases.
What do the latest results show for Danaher (DHR)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $6.26B.
Research dated 2026-09-12.
Latest revenue rose from both the preceding period and the comparable prior period, while reported earnings exceeded expectations and revenue also cleared consensus. Operating profit nevertheless declined: gross profit improved only slightly from the preceding period as selling and administrative expense and research spending increased, leaving less of the revenue gain to reach the bottom line. Operating cash flow strengthened, providing a cleaner sign of financial momentum than earnings alone.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $6.26B Jun 26, 2026
- Latest quarter · R&D
- $412.00M Jun 26, 2026
- Latest quarter · SG&A
- $2.07B Jun 26, 2026
- Latest quarter · FMP standardized operating result
- $1.13B Jun 26, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 26, 2026 | $6.26B | $412.00M | $2.07B | $1.13B |
| Mar 27, 2026 | $5.95B | $387.00M | $1.86B | $1.34B |
| Dec 31, 2025 | $6.84B | $438.00M | $2.03B | $1.50B |
| Sep 26, 2025 | $6.05B | $378.00M | $1.99B | $1.15B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $6.26B Jul 21, 2026
- Latest report · revenue estimate
- $6.12B Jul 21, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 21, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 21, 2026 | $6.26B | $6.12B | $1.9400 | $1.8500 |
| Apr 21, 2026 | $5.95B | $5.98B | $2.0600 | $1.9400 |
| Jan 28, 2026 | $6.84B | $6.81B | $2.2300 | $2.1600 |
| Oct 21, 2025 | $6.05B | $6.00B | $1.8900 | $1.7200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $6.26B | $870M | $1.23 (diluted) |
| Q1 FY2026 | $5.95B | $1.03B | $1.45 (diluted) |
| Q4 FY2025 | $6.84B | $1.20B | $1.68 (diluted) |
| Q3 FY2025 | $6.05B | $908M | $1.27 (diluted) |
What are the financial strengths and risks for Danaher (DHR)?
Short answer
Cash and short-term investments were $4.35B at the Jun 26, 2026 balance-sheet date. Operating cash flow was $1.53B for the quarter ended Jun 26, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has exceeded capital expenditure throughout the displayed history, giving Danaher meaningful internally generated funding. Liquidity covers near-term obligations, but debt materially exceeds cash and investments, so sustained cash conversion matters more than the headline cash balance. The longer-running caution is that annual revenue stabilized before returning to growth while net income continued to recede; weaker laboratory, bioprocessing or diagnostic activity could pressure both instrument demand and the recurring consumables attached to those workflows.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $1.53B Jun 26, 2026
- Previous quarter · operating cash flow
- $1.32B Mar 27, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 26, 2026 | $1.53B | −$269.00M |
| Mar 27, 2026 | $1.32B | −$237.00M |
| Dec 31, 2025 | $2.12B | −$371.00M |
| Sep 26, 2025 | $1.66B | −$292.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Danaher (DHR)?
Short answer · as of
The next earnings report is expected on Oct 20, 2026.
Research dated 2026-09-12.
Danaher’s scheduled earnings release needs to be read across revenue, gross profit and operating expense together: another sales increase would be less persuasive if operating profit again moved the other way. Cash conversion, capital spending and the recent decline in cash and short-term investments will show whether growth is rebuilding financial flexibility or merely absorbing it. Consensus assumes continued expansion across the forecast horizon, so recurring revenue and demand from biopharmaceutical, research and diagnostic customers are the operating checks behind that expectation.
How does Danaher compare with its peers?
Short answer
Danaher's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Unlike a focused diagnostics or laboratory-instrument business, Danaher combines life-science research, bioprocessing, clinical testing and applied industrial analysis within one portfolio. Its economic distinction is the pairing of sophisticated systems with reagents, consumables, software and services used after placement; the recurring revenue category is far larger than the nonrecurring category. That mix spreads demand across laboratories, drug manufacturers, hospitals and industrial customers, while leaving performance tied to activity across several specialized workflows rather than a single product cycle.
| Company | Price | Market value | Score |
|---|---|---|---|
| $391.95 Oct 2, 2026 | $138B | 94 5-pillar Oct 4, 2026 | |
| $273.04 Oct 2, 2026 | $41.3B | 94 5-pillar Oct 4, 2026 | |
| $518.39 Oct 2, 2026 | $40.9B | 92 5-pillar Oct 4, 2026 | |
| $403.04 Oct 2, 2026 | $218B | 85 5-pillar Oct 4, 2026 | |
| $167.77 Oct 2, 2026 | $47.4B | 84 5-pillar Oct 4, 2026 | |
| $39.92 Oct 2, 2026 | $95.9B | 83 5-pillar Oct 4, 2026 | |
| $1486.19 Oct 2, 2026 | $30.0B | 82 5-pillar Oct 4, 2026 | |
| $233.24 Oct 2, 2026 | $25.7B | 74 5-pillar Oct 4, 2026 | |
| $258.21 Oct 2, 2026 | $42.5B | 73 5-pillar Oct 4, 2026 | |
| $308.49 Oct 2, 2026 | $25.3B | 71 5-pillar Oct 4, 2026 | |
| Danaher (DHR) — this page | $214.06 | $150B | 68 |
| $27.80 Oct 2, 2026 | $158B | 68 5-pillar Oct 4, 2026 | |
| $654.80 Oct 2, 2026 | $242B | 68 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $195.00 – $250.00
- Consensus target
- $227.62
- Median target
- $230.00
Consensus record · Captured .
Measured against a quoted price of $214.06 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Aug 21, 2026
- Transactions
- 34
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 3
- Other transactions
- 31
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 82.7% Period end Jun 30, 2026
- Previous quarter · ownership
- 80.8% Prior to period end Jun 30, 2026
- Reporting holders
- 2,187 Period end Jun 30, 2026
- Previous quarter · holders
- 2,250 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 55,084,630 |
| Vanguard Capital Management LLC | 41,377,076 |
| Fmr LLC | 29,540,895 |
| State Street Corp | 28,456,019 |
| Wellington Management Group Llp | 16,316,834 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Danaher (DHR)?
DHR Healthcare Stock FAQ
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What makes Danaher’s revenue recurring?
Danaher sells reagents, consumables, software and services alongside instruments used in bioprocessing, laboratory research, clinical diagnostics and applied analysis. Those continuing purchases account for most reported revenue.
Why can Danaher’s revenue rise while operating profit falls?
In the latest period, gross profit improved only modestly from the preceding period while selling and administrative expense and research spending rose. The added operating expense more than absorbed the gross-profit increase.
Which customers drive Danaher’s Life Sciences demand?
Pharmaceutical and biopharmaceutical companies, universities, medical schools, research institutions and industrial manufacturers buy Danaher’s research instruments, genomics tools, bioprocess systems and related consumables. Their research and production activity influences both equipment purchases and continuing workflow demand.
How exposed is Danaher to debt despite its cash generation?
Debt remains well above cash and investments, despite operating cash flow consistently covering capital expenditure. That makes continued cash conversion central to preserving flexibility.
What is the DHR stock price today?
The last price recorded on this page for Danaher Corporation (DHR) is $214.06, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DHR price target?
The analyst consensus price target for Danaher Corporation (DHR) is $227.62 (range $195.00 to $250.00, median $230.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are DHR's next earnings?
The next earnings date listed on this page for Danaher Corporation (DHR) is Oct 20, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (84 figures)
The 84 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 2200 Pennsylvania AVE. N.W., Suite 800W, Washington, DC, 20037-1701 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "2200 Pennsylvania Avenue, NW, Washington, DC, 20037-1701, US". |
FMP — 74 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $214.06 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:04:47.759Z. | |
px.change | Change on the day | +1.09% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $150B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:02:30.000Z. Captured from FMP at 2026-10-04T21:04:46.469Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$2.30 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $6.26B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $160.93–$242.80 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 37.89 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.89M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.81 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Rainer Blair | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Mitchell Rales — Co-Founder & Director | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 59,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $29.45B, net result $6.43B; FY2022 revenue $26.64B, net result $7.21B; FY2023 revenue $23.89B, net result $4.76B; FY2024 revenue $23.88B, net result $3.90B; FY2025 revenue $24.57B, net result $3.61B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Revenue from Contract with Customer, Measurement, Recurring $20.13B · Revenue from Contract with Customer, Measurement, Nonrecurring $4.44B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 58.5% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-26.revenue_k | Revenue — period end 2026-06-26 | $6.26B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-26.rd_k | R&D — period end 2026-06-26 | $412.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-26.sga_k | SG&A — period end 2026-06-26 | $2.07B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-26.operating_result_k | FMP standardized operating result — period end 2026-06-26 | $1.13B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-27.revenue_k | Revenue — period end 2026-03-27 | $5.95B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-27.rd_k | R&D — period end 2026-03-27 | $387.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-27.sga_k | SG&A — period end 2026-03-27 | $1.86B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-27.operating_result_k | FMP standardized operating result — period end 2026-03-27 | $1.34B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $6.84B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $438.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $2.03B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $1.50B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.revenue_k | Revenue — period end 2025-09-26 | $6.05B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.rd_k | R&D — period end 2025-09-26 | $378.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.sga_k | SG&A — period end 2025-09-26 | $1.99B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.operating_result_k | FMP standardized operating result — period end 2025-09-26 | $1.15B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-21.revenue_actual | Revenue · reported — report date 2026-07-21 | $6.26B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.revenue_estimated | Revenue · estimate — report date 2026-07-21 | $6.12B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_actual | EPS · reported — report date 2026-07-21 | $1.9400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_estimated | EPS · estimate — report date 2026-07-21 | $1.8500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-21.revenue_actual | Revenue · reported — report date 2026-04-21 | $5.95B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-21.revenue_estimated | Revenue · estimate — report date 2026-04-21 | $5.98B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-21.eps_actual | EPS · reported — report date 2026-04-21 | $2.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-21.eps_estimated | EPS · estimate — report date 2026-04-21 | $1.9400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.revenue_actual | Revenue · reported — report date 2026-01-28 | $6.84B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.revenue_estimated | Revenue · estimate — report date 2026-01-28 | $6.81B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.eps_actual | EPS · reported — report date 2026-01-28 | $2.2300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.eps_estimated | EPS · estimate — report date 2026-01-28 | $2.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-21.revenue_actual | Revenue · reported — report date 2025-10-21 | $6.05B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-21.revenue_estimated | Revenue · estimate — report date 2025-10-21 | $6.00B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-21.eps_actual | EPS · reported — report date 2025-10-21 | $1.8900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-21.eps_estimated | EPS · estimate — report date 2025-10-21 | $1.7200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $4.35B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $1.53B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-26. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $1.59B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $26.56B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.87× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-26.operating_cash_flow_m | Operating cash flow — period end 2026-06-26 | $1.53B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-27.operating_cash_flow_m | Operating cash flow — period end 2026-03-27 | $1.32B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-26.capex_m | Capital expenditure (reported) — period end 2026-06-26 | −$269.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-27.capex_m | Capital expenditure (reported) — period end 2026-03-27 | −$237.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $2.12B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$371.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-26.operating_cash_flow_m | Operating cash flow — period end 2025-09-26 | $1.66B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-26.capex_m | Capital expenditure (reported) — period end 2025-09-26 | −$292.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $195.00 – $250.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $227.62 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $230.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 34 transactions · 0 purchases, 3 sales, 31 other transactions · 18 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Aug 21, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 82.7% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 80.8% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 2,187 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 2,250 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 55,084,630 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 41,377,076 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Fmr LLC — shares in provider snapshot | 29,540,895 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | State Street Corp — shares in provider snapshot | 28,456,019 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Wellington Management Group Llp — shares in provider snapshot | 16,316,834 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 20, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-08-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 34.50× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $4.35B at Jun 26, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-26. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.52 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-03, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.71% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-21.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($6.26B) with the recorded estimate ($6.12B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-21.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.9400) with the recorded estimate ($1.8500) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 68 of 100 · Strong · pillars 82 / 44 / 50 / 36 / 76 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 68 (stored snapshot Oct 3, 2026) → 68 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-26. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-26.revenue_k,fin.q_table.depth.2026-06-26.rd_k,fin.q_table.depth.2026-06-26.sga_k,fin.q_table.depth.2026-06-26.operating_result_k,fin.q_table.depth.2026-03-27.revenue_k,fin.q_table.depth.2026-03-27.rd_k,fin.q_table.depth.2026-03-27.sga_k,fin.q_table.depth.2026-03-27.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-26.revenue_k,fin.q_table.depth.2025-09-26.rd_k,fin.q_table.depth.2025-09-26.sga_k,fin.q_table.depth.2025-09-26.operating_result_k. - Earnings-history note. Source series as of 2026-07-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-21.revenue_actual,earn.history.depth.2026-07-21.revenue_estimated,earn.history.depth.2026-07-21.revenue_actual.comparison,earn.history.depth.2026-07-21.eps_actual.comparison,earn.history.depth.2026-07-21.eps_actual,earn.history.depth.2026-07-21.eps_estimated,earn.history.depth.2026-04-21.revenue_actual,earn.history.depth.2026-04-21.revenue_estimated,earn.history.depth.2026-04-21.eps_actual,earn.history.depth.2026-04-21.eps_estimated,earn.history.depth.2026-01-28.revenue_actual,earn.history.depth.2026-01-28.revenue_estimated,earn.history.depth.2026-01-28.eps_actual,earn.history.depth.2026-01-28.eps_estimated,earn.history.depth.2025-10-21.revenue_actual,earn.history.depth.2025-10-21.revenue_estimated,earn.history.depth.2025-10-21.eps_actual,earn.history.depth.2025-10-21.eps_estimated. - Cash-flow note. Source series as of 2026-06-26. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-26.operating_cash_flow_m,fin.opcf.depth.2026-03-27.operating_cash_flow_m,fin.opcf.depth.2026-06-26.capex_m,fin.opcf.depth.2026-03-27.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-26.operating_cash_flow_m,fin.opcf.depth.2025-09-26.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Revenue from Contract with Customer, Measurement, Recurring: $20.13B; Revenue from Contract with Customer, Measurement, Nonrecurring: $4.44B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-26 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-26 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $26.56B; Liquidity basis: cash and short-term investments; Total liabilities: $39.79B; Cash and short-term investments: $4.35B; Cash and investments: $5.94B; Long-term investments: $1.59B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-26 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 3823 — Industrial Instruments For Measurement, Display, and Control. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-21 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $5.94B; Cash and short-term investments: $4.35B; Long-term investments: $1.59B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-26 | COMPUTED | Computed from the balance sheet |
| Cash against market value | As of: 2026-06-26; Cash basis: cash and short-term investments; Net cash: -$22.21B; Total debt: $26.56B; Cash and investments: $4.35B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-26 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.25; Current ratio: 1.65; Debt to equity: 0.51; Net margin: 15.9%; Gross margin: 58.5%; Operating margin: 20.4%; Return on assets: 4.3%; Return on equity: 7.7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-20; EPS estimate: $1.91 per share; Revenue estimate: $6.55B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-26 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
Data provided for informational purposes only.
ETFs that hold DHR
Funds in our ETF coverage that list DHR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| FM Focus Equity ETF (FMCX) | 4.33% | |
| Madison Covered Call ETF (CVRD) | 4.18% |